Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
fatty liver disease
Research
Organoids offer NAFLD insights and potential drug target
There's less focus on early-stage NAFLD treatments compared to NASH meds, largely because there are no reliable models. Organoids could change that.
Helen Floersh
Feb 28, 2023 12:27pm
J&J strikes down Arrowhead NASH pact; fate of hep B deal unknown
Feb 15, 2023 9:22am
Madrigal's stock enters orbit after 2nd phase 3 NASH success
Dec 19, 2022 10:05am
Nicotine-nomming gut bacteria could protect against NASH
Oct 21, 2022 1:05pm
Rivus raises $132M series B as metabolic pipeline heats up
Sep 22, 2022 10:41am
Pfizer gains fast-track tag for previously shelved NASH drug
May 26, 2022 9:05am
